Obalon Therapeutics said it secured $30 million to fund development of its ingestible weight-loss device, the Obalon balloon.
NEW YORK (Reuters Health) – More than 20 years of evidence suggests that bariatric surgery produces greater weight loss and more type 2 diabetes remissions than nonsurgical treatments for the obese, according to a review.
Patients in a clinical study who had bariatric surgery saw sustained improvements in symptoms of Type II diabetes out to 3 years after the procedure, some reporting complete diabetes remission, researchers said.
MASSDEVICE ON CALL — Researchers this week unveiled the 1st early results from a benchmark clinical trial evaluating bariatric weight-loss surgery in severely obese adolescents.
The investigators reported "encouraging" outcomes in the more than 240 patients who were, on average, 17 years old, finding "few short-term complications" in the 30 days following treatment.